에 대한 최신 뉴스 Akero Therapeutics (NASDAQ:AKRO) 주식

Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Brinker

Equities

Mid Cap

News

Movers

Trading Ideas

AKRO

Brighthouse Financial, Inc. - Common Stock

Hims & Hers Health, Inc. Class A Common Stock

HIMS

SGRY

VIAV

이 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아케로 테라퓨틱스(NASDAQ:AKRO)의 주가는 회사가 에프룩시퍼민(Efruxifermin)에 대한 SYMMETRY 2B상 연구의 96주차 예비 결과를 보고한 후 주가는 106.57% 급등했다. 몇몇 애널리스트들이 목표 주가를 상향 조정했다.

아케로 테라퓨틱스, 브링커 인터내셔널, 비아비 등 지난주 최대 상승한 중형주 (1월 27일-1월 31일)

Akero Therapeutics Inc

Akropolis

<h3>Companies Reporting Before The Bell</h3>
• Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) is projected to report earnings for its Fiscal Year 2024. 
• Bright Scholar Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEDU#NYSE">BEDU</a>) is expected to report earnings for its second quarter. 
• Kandi Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNDI#NASDAQ">KNDI</a>) is estimated to report earnings for its fourth quarter. 
• SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) is projected to report quarterly loss at $0.46 per share on revenue of $6.48 million. 
• Provident Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROV#NASDAQ">PROV</a>) is expected to report quarterly earnings at $0.24 per share on revenue of $9.86 million. 
• Toyo Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOYO#NASDAQ">TOYO</a>) is estimated to report earnings for its Fiscal Year 2024. 
• InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $77.57 million. 
• BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) is likely to report quarterly earnings at $0.76 per share on revenue of $263.57 million. 
• Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) is projected to report quarterly earnings at $0.51 per share on revenue of $556.31 million. 
• Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is projected to report quarterly earnings at $4.75 per share on revenue of $1.89 billion. 
• Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) is estimated to report quarterly earnings at $0.96 per share on revenue of $662.30 million. 
• Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) is expected to report quarterly earnings at $0.24 per share on revenue of $132.48 million. 
• Silicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILC#NASDAQ">SILC</a>) is likely to report quarterly loss at $0.37 per share on revenue of $14.37 million. 
• Rithm Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPT#NYSE">RPT</a>) is projected to report earnings for its first quarter. 
• Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) is estimated to report earnings for its first quarter. 
• Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) is likely to report quarterly earnings at $4.04 per share on revenue of $1.12 billion. 
• Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $16.16 million. 
• Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $27.99 million. 
• Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $3.85 billion. 
<h3>Companies Reporting After The Bell</h3>
• Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $169.00 million. 
• Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) is projected to report quarterly loss at $0.25 per share on revenue of $116.40 million. 
• SunCar Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) is projected to report earnings for its Fiscal Year 2024. 
• EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $306.17 million. 
• Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) is projected to report quarterly loss at $0.63 per share on revenue of $288.13 million. 
• Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) is likely to report quarterly earnings at $1.38 per share on revenue of $1.97 billion. 
• Firstsun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) is expected to report earnings for its first quarter. 
• CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) is estimated to report quarterly loss at $0.75 per share on revenue of $1.65 billion. 
• Leggett &amp; Platt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $1.02 billion. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is estimated to report quarterly earnings at $1.14 per share on revenue of $2.37 billion. 
• Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $127.51 million. 
• Financial Institutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FISI#NASDAQ">FISI</a>) is likely to report quarterly earnings at $0.80 per share on revenue of $56.32 million. 
• Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is likely to report quarterly earnings at $1.68 per share on revenue of $6.12 billion. 
• Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) is estimated to report earnings for its first quarter. 
• Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) is expected to report quarterly earnings at $1.30 per share on revenue of $546.93 million. 
• Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) is estimated to report quarterly earnings at $1.14 per share on revenue of $276.83 million. 
• Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $162.83 million. 
• PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $243.68 million. 
• Cincinnati Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CINF#NASDAQ">CINF</a>) is likely to report quarterly loss at $0.52 per share on revenue of $2.71 billion. 
• F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) is projected to report quarterly earnings at $3.22 per share on revenue of $703.63 million. 
• NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is expected to report quarterly earnings at $2.60 per share on revenue of $2.83 billion. 
• Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is estimated to report quarterly earnings at $1.50 per share on revenue of $1.24 billion. 
• Gerdau (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGB#NYSE">GGB</a>) is estimated to report earnings for its first quarter. 
• Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is expected to report quarterly earnings at $2.29 per share on revenue of $758.46 million. 
• Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $7.31 billion. 
• Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $1.41 billion. 
• SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $160.54 million. 
• Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $-28 million. 
• Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $34.94 million. 
• Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $7.58 million. 
• Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $119.20 million. 
• SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is expected to report quarterly earnings at $2.32 per share on revenue of $661.98 million. 
• CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) is expected to report earnings for its first quarter. 
• CNO Finl Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>) is likely to report quarterly earnings at $0.80 per share on revenue of $975.80 million. 
• UFP Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPI#NASDAQ">UFPI</a>) is projected to report quarterly earnings at $1.57 per share on revenue of $1.61 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is projected to report quarterly earnings at $1.46 per share on revenue of $838.72 million. 
• Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) is projected to report quarterly earnings at $1.77 per share on revenue of $544.94 million. 
• Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is projected to report quarterly earnings at $0.61 per share on revenue of $680.54 million. 
• Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) is projected to report quarterly loss at $0.10 per share on revenue of $884.92 million. 
• Piedmont Office Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $141.29 million. 
• Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) is estimated to report quarterly earnings at $0.47 per share on revenue of $334.61 million. 
• Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) is expected to report quarterly earnings at $4.38 per share on revenue of $4.16 billion. 
• COPT Defense Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $185.78 million. 
• Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) is projected to report quarterly earnings at $1.23 per share on revenue of $2.82 billion. 
• Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $863.31 million. 
• Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $1.28 billion. 
• NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $2.10 billion. 
• Northwest Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWBI#NASDAQ">NWBI</a>) is estimated to report quarterly earnings at $0.24 per share on revenue of $142.16 million. 
• RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $28.98 million. 
• Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $53.04 million. 
• Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $44.21 million. 
• Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is likely to report earnings for its first quarter. 
• Alerus Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $66.19 million. 
• Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $561.40 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ABCB

ALRS

AMKR

ARLP

BEDU

BMRC

BYON

CDNS

CINF

EFSC

EZPW

FBRT

FFIV

FISI

Fomento Economico Mexicano S.A.B. De C.V.

FSBC

FSUN

GFAI

HLIT

INMD

KFRC

KNDI

MBIN

NTST

NWBI

NXPI

OPRA

PERF

PROV

RMBS

RVTY

SANM

SBAC

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SEVN

SILC

SPCB

TOYO

UCTT

UFPI

WELL

Earnings Scheduled For April 28, 2025

Analysts from Goldman Sachs have warned that the U.S. tariffs on Chinese imports could put up to 16 million jobs in China at risk, particularly in the manufacturing sector.
What Happened: The bank stated that persistently high U.S.-China tariffs and a significant drop in Chinese exports could put pressure on labor markets. The jobs under threat are primarily involved in the production of exports to the U.S., with nearly a quarter in the wholesale and retail sectors, <a href="https://www.scmp.com/economy/china-economy/article/3308140/us-tariffs-could-endanger-16-million-export-jobs-china-goldman-sachs">reported</a> the South China Morning Post.
"If high US-China tariffs were to persist and Chinese exports were to fall precipitously, labor markets would surely feel the pressure," stated the report
This year, the U.S. has levied tariffs of 145% on Chinese imports, pushing the effective tariff rate to around 156%. In retaliation, Beijing has imposed a 125% tariff on all U.S. goods, in addition to previous duties.
Goldman Sachs highlighted that communication equipment, apparel, and chemical products are more susceptible due to their significant share in US-bound exports from China. The bank also proposed that Chinese manufacturers could relocate production to third countries to circumvent high duties.
The report also noted that the U.S. removal of tariff exemptions for low-value package shipments is putting &#8217;employment pressure&#8217; on China's retail and wholesale sectors.
SEE ALSO:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/04/45011721/intel-just-announced-q2-guidance-below-estimates-why-the-stock-is-tumbling" target="_blank" rel="noreferrer noopener">Intel Just Announced Q2 Guidance Below Estimates: Why The Stock Is Tumbling</a>
Why It Matters: Earlier this month,&nbsp;<a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns">Goldman Sachs warned</a>&nbsp;about a sluggish economic recovery for China and deep labor market consequences. As per the bank, the tariffs could reduce Chinese real GDP by 2.6 percentage points — with a 2.2 percentage point impact hitting as soon as 2025.
The bank also predicted that the possibility of a U.S.-China decoupling could lead to a massive<a href="https://www.benzinga.com/25/04/44787496/goldman-sachs-warns-25-trillion-sell-off-in-the-extreme-event-of-us-china-decoupling-as-scott-bessent-says-everything-is-on-the-table"> $2.5 trillion </a>sell-off. In an extreme scenario, investors from both countries might be forced to divest their holdings of equities and debt instruments. 
Meanwhile, S&amp;P Global Ratings on Friday stated that Trump's tariff increases are expected to primarily affect China's coastal provinces, including Guangdong, Jiangsu, Shandong, and Zhejiang, along with Shanghai, a key port and financial hub.
That being said, a possible easing of trade tensions,&nbsp;China last week,<a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts"> reportedly began </a>exempting&nbsp;some U.S. imports from high tariffs, including pharmaceutical imports and aerospace parts. Companies in China have been approached by officials to identify essential U.S. goods that are difficult to replace. Furthermore, the 24-member Politburo, led by President Xi Jinping, committed to stabilizing China's economy and employment, and called for support measures for those impacted by tariffs following a meeting last week.
The ADR of Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) climbed 0.8% to close at $120.28 on Friday, while that of PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) rose 0.72% to close at $104.01. Meanwhile, the ADR of NetEase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) slid 0.05% to close at $105.86, as per <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">BenzingaPro</a>.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45027945/does-anybody-honestly-believe-manufacturing-is-coming-back-to-the-us-one-person-asked-says-youd-have-to-pay-" target="_blank" rel="noreferrer noopener">&#8216;Does Anybody Honestly Believe Manufacturing Is Coming Back To The US?&#8217; One Person Asked. Says, &#8216;You&#8217;d Have To Pay Americans $40–$50/Hr&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

BABA

NTES

Citigourp Global Markets 2% Protected Notes Linked To The Djia

16 Million Jobs At Risk In China As US Tariffs Hammer Manufacturing And Retail Sectors, Goldman Sachs Warns

Pershing Square's Bill Ackman has hailed Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos-backed Slate Auto as the company recently revealed its $20,000 EV truck.
What Happened: Quoting a post that shared a Slate Auto commercial on social media platform X, Ackman hailed the company's modular approach to its vehicle on Saturday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is a going to be a big success. We all want more simplicity and flexibility in our lives. <a href="https://t.co/t7o7VYfBFM">https://t.co/t7o7VYfBFM</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1916123387669225910?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"This is a going to be a big success. We all want more simplicity and flexibility in our lives," Ackman shared in his post.
Why It Matters: Slate Auto has only one product on offer, which it calls the ‘Blank Slate.' In its base form, it is a two-seater EV pickup truck in grey with a 150-mile range, but customers can personalize the car in whatever way they want, including a 5-seater SUV.
The company says that with the federal EV credit, the <a href="https://www.benzinga.com/tech/25/04/45006513/jeff-bezos-backed-tesla-rival-unveils-20000-modular-ev-pickup-truck-with-customization-at-the-forefront">car could cost $20,000</a>, which is significantly cheaper than the likes of Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Cybertruck or Rivian Automotive Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) R1T.
While Slate Auto says the company aims to begin deliveries by 2026, the EV pickup truck has already garnered a lot of <a href="https://www.benzinga.com/tech/25/04/44784826/jeff-bezos-backed-slate-auto-to-take-on-elon-musks-tesla-rivian-with-budget-ev-pickup-report">buzz on social media</a> platforms like Reddit.&nbsp;
Interestingly, the release comes at a time when the domestic EV market in the U.S. is <a href="https://www.benzinga.com/25/04/44755934/us-q1-ev-sales-data-shows-106-yoy-growth-tesla-experiences-decline-but-still-dominates-domestic-ev-sales">experiencing a surge</a>, which Slate Auto could take advantage of given its product's competitive pricing.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="214" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-1024x214.jpg" alt="" class="wp-image-890272" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-1024x214.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-300x63.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-768x160.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN-1536x321.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033155/AMZN.jpg 1647w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Amazon scores Well on metrics like Momentum, Growth, and Quality, and has a Satisfactory score in the Value metric. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/04/45032179/tesla-reportedly-developing-a-cheaper-model-y-e80-variant-with-fewer-features-in-china">Tesla Reportedly Developing A Cheaper Model Y &#8216;E80&#8217; Variant With Fewer Features In China</a></li>
</ul>
Image Via Slate Auto

Tech

General

AMZN

RIVN

TSLA

Bill Ackman Hails Jeff Bezos-Backed Tesla Rival Slate Auto, Says It Will Be 'A Big Success'

Huawei Technologies is reportedly preparing to test its most powerful artificial intelligence processor to date, with hopes of <a href="https://www.benzinga.com/25/03/44356270/huawei-develops-in-house-chips-to-counter-us-sanctions-and-leap-ahead-in-the-tech-war">replacing high-end chips</a> from U.S. giant Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), even as U.S. sanctions continue to stifle China&#8217;s semiconductor ambitions.
What Happened: Huawei has begun the testing phase of its new AI chip, the Ascend 910D, which is designed to rival Nvidia's flagship processors, <a href="https://www.wsj.com/tech/chinas-huawei-develops-new-ai-chip-seeking-to-match-nvidia-8166f606?mod=tech_lead_pos1">reported</a> the Wall Street Journal on Sunday, citing people familiar with the matter.
The chip will undergo a series of technical tests, with samples expected to be ready by late May. The Ascend 910D aims to surpass Nvidia's H100 chip, a popular choice for AI training tasks.
This move marks a significant step forward for Huawei's semiconductor division, which has faced substantial challenges due to <a href="http://v/">U.S. sanctions over</a> the past six years.
See Also:&nbsp;<a href="https://benzinga.com/25/04/45003790/mark-cuban-slams-amazon-for-ripping-off-american-sellers-as-tariffs-are-predicted-to-boost-ecommerce-brands-profi" target="_blank" rel="noreferrer noopener">Mark Cuban Slams Amazon For ‘Ripping Off American Sellers' As Trump Tariffs Are Predicted To Boost Ecommerce Brands' Profits</a>
This year, Huawei plans to ship over 800,000 Ascend 910B and 910C chips. Customers include state-run telecoms and companies like ByteDance, the report noted, citing the sources. 
However, Huawei has been struggling to manufacture these chips on a large scale due to <a href="https://www.benzinga.com/25/04/44963176/chinese-tech-firms-led-by-alibaba-hoard-nvidia-ai-chips-amid-us-sanctions">obstacles in its supply chain</a>. The company has been excluded from working with Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Its closest alternative, Semiconductor Manufacturing International, is also restricted from acquiring the latest chip-making technology.
Why It&#8217;s Important: Earlier this month, the U.S. government placed Nvidia's H20 chip—its most advanced processor available for sale in China without a license—on a list of semiconductors facing sales restrictions.
Nvidia revealed that this move would lead to a<a href="https://www.benzinga.com/25/04/44830406/nvidia-to-take-55-billion-hit-over-china-chip-export-restrictions-but-top-analyst-dan-ives-says-hes-not-overly-concerned-all-part-of-the-high-game-of-poker"> $5.5 billion financial hit</a>.
On Sunday, Chamath Palihapitiya spoke about how <a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Huawei has effectively executed</a> a &#8220;low-end disruptor&#8221; strategy. This strategy focuses on creating products that match or exceed the quality of industry leaders, but at a more affordable price.
He highlighted several companies Huawei has already surpassed, including Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) and Nokia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>).
Previously, the SPAC king raised concerns that <a href="https://in.benzinga.com/markets/25/04/44891778/nvidia-not-acting-in-us-interests-says-chamath-palihapitiya-questions-how-alibaba-or-deepseek-are-one-step-ahead">Nvidia may not be prioritizing</a> the best interests of the U.S.
Benzinga Edge Stock Rankings places Nvidia&#8217;s growth score in the 94th percentile. Curious how other chip stocks compare? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to discover more</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/trading-ideas/movers/25/04/45029805/what-caused-sam-altman-founded-world-network-token-to-soar-57-in-a-week" target="_blank" rel="noreferrer noopener">What Caused Sam Altman-Founded World Network Token To Soar 57% in a Week? What Caused Sam Altman-Founded World Network Token To Soar 57% in a Week?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Media

ERIC

MSFT

Nvidia Faces New Challenge As Huawei Tests Powerful Ascend 910D AI Chip Amid US Sanctions, Aiming To Disrupt High-End Market: Report

Global defense budgets reached unprecedented levels in 2024, driven by mounting conflicts and geopolitical strains. A new report from the Stockholm International Peace Research Institute (SIPRI) showcases a sensational increase in military spending across the globe.
What Happened: According <a href="https://www.sipri.org/media/press-release/2025/unprecedented-rise-global-military-expenditure-european-and-middle-east-spending-surges">to</a> SIPRI, military expenditure rose 9.4% to $2.72 trillion. This marks the most drastic annual increase since the Cold War concluded. All regions reported higher defense outlays, with Europe and the Middle East demonstrating particularly speedy growth. 
More than 100 nations enhanced their military budgets, often reallocating funds from other crucial sectors. U.S. military expenditure touched $997 billion, making up 66% of NATO&#8217;s total and 37% of global defense spending.
See Also: <a href="https://www.benzinga.com/news/25/04/44889497/its-offensive-and-just-plain-wrong-trumps-budget-proposal-to-eliminate-head-start-affecting-over-1-million-parents">&#8216;It&#8217;s Offensive And Just Plain Wrong&#8217;—Trump&#8217;s Budget Proposal To Eliminate Head Start, Affecting Over 1 Million Parents</a>
Why It Matters: Europe&#8217;s military expenditure, including Russia, soared 17%, moving past Cold War-era numbers. Russia&#8217;s defense budget alone rose by 38% to an approximate $149 billion, making up 7.1% of its Gross Domestic Product. 
Ukraine, despite major financial difficulties, increased military spending by 2.9% to $64.7 billion, with its defense budget now taking up all available tax revenue.
The report underscores rising concerns about the long-term impact of prioritizing military budgets over social and economic necessities. 
SIPRI warns that the trend could restructure societies for decades to come. In Europe, the ongoing war in Ukraine and ambiguity surrounding U.S. NATO support have prompted increased defense spending.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45030778/trump-running-american-economy-like-a-mafia-don-economist-craig-shapiro-draws-parallels-with-russias-president">Trump Running American Economy Like A &#8216;Mafia Don&#8217;: Economist Craig Shapiro Draws Parallels With Russia&#8217;s President</a></li>
</ul>
Image via Shutterstock

Global

Economics

Global Defense Budgets Surge To $2.7 Trillion As Europe And Middle East Lead Steepest Increase Since Cold War: Report

Buybacks

MIELY

Mitsubishi Electric Launches Share Buyback Program For 60M Shares Worth Up To JPY 100B

In a recent private event,&nbsp;Donald Trump Jr., son of the U.S. President, voiced his support for enhanced business cooperation with Eastern Europe.
What Happened: Trump Jr. underscored his close connections to the region during his address at the Trump Business Vision 2025 event organized by businessman Zoltán Aczél and Portfolio at Budapest, Hungary. He spotlighted his Czechoslovakian roots and language proficiency owing to his mother late Ivana Trump, and applauded the region&#8217;s dramatic evolution over the past five decades, <a href="https://www.portfolio.hu/en/economy/20250425/donald-trump-jr-we-want-to-do-a-lot-of-good-business-with-our-friendly-allies-757309">reported</a> Portfolio.
As the&nbsp;Executive Vice President of the&nbsp;Trump Organization, Trump Jr. praised Hungary&#8217;s robust political leadership, specifically Prime Minister Viktor Orbán. He expressed belief in the potential for successful collaboration between American and Hungarian businesses.
He is hopeful that the U.S.-Eastern Europe ties would generate a lot of business amid threats facing the U.S., Hungary and the Central and Eastern European region.
&#8220;I understand the threat that looms from so many places and it&#8217;s not the evil boogeyman of Russia, but likely China,&#8221; pointed out the U.S. President&#8217;s son. 
Trump Jr. recognized the necessity to diversify the U.S. economy&#8217;s dependencies, pointing out the high concentration of pharmaceutical production in China and advanced chip technology in Taiwan. He proposed that Eastern Europe, with its committed workforce and lower labor costs, could assume many activities currently outsourced to China.
&#8220;Pulling away from China is the first step, the dependence is too high,&#8221; stated Trump Jr.
SEE ALSO:&nbsp;<a href="https://benzinga.com/general/sports/25/04/45027895/why-shaq-wont-share-his-500-million-fortune-with-his-kids-we-aint-rich-im-rich-im-not-going-to-hand-it-to-you-you-gotta-earn-it" target="_blank" rel="noreferrer noopener">Why Shaq Won't Share His $500 Million Fortune With His Kids: ‘We Ain't Rich. I'm Rich. I'm Not Going to Hand It to You, You Gotta Earn It&#8217; &#8211; Benzinga</a>
Why It Matters: This comes at a time when the U.S. is experiencing strained relations with China. The ongoing trade war with China has led to a significant decrease in U.S. imports <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">from the</a> Asian nation, while China&#8217;s Ministry of Commerce has <a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis">denied rumors</a> of ongoing trade discussions with the U.S.
Against this backdrop, analysts suggest there are concerns that China <a href="https://www.benzinga.com/news/global/25/04/44892820/xi-jinping-could-woo-europe-with-a-potential-china-deal-to-undercut-trumps-tariff-strategy-expert-warns">might leverage</a> the strained U.S.-EU relations to its benefit, leading Beijing to shift the majority exports to Europe.
Trump Jr.&#8217;s call for increased cooperation with Eastern Europe could be seen as a strategic move to diversify the U.S.&#8217;s economic dependencies amid these ongoing tensions. Despite not being a member of the Trump administration, Trump Jr. was hopeful about the renewal of the expired double tax treaty between the U.S. and Hungary, citing the strong relationship between his father, Donald Trump and Prime Minister Orbán.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45022796/this-is-not-really-how-i-pictured-my-life-at-30-air-force-vet-says-he-works-retail-for-18-an-hour-and-feels-" target="_blank" rel="noreferrer noopener">&#8216;This Is Not Really How I Pictured My Life At 30&#8217;—Air Force Vet Says He Works Retail For $18 An Hour And &#8216;Feels Like A Loser&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Jr. Leans On His Czech Roots To Boost US-Eastern Europe Ties While 'Pulling Away' From China: 'It's Not The Evil Boogeyman Of Russia, But Likely China'

Consolidated Financial Results Revenue: 5,521.7 billion yen (5% increase year-on-year) Operating profit: 391.8 billion yen (19% increase year-on-year) Profit before income taxes: 437.2 billion yen (20% increase year-on-year) Net profit attributable to Mitsubishi Electric Corp. stockholders: 324.0 billion yen (14% increase year-on-year)

Mitsubishi Electric's FY25 Revenue ¥5.521T, Up 5% YoY; Net Profit Attributable To Stockholders ¥324B, Up 14% YoY

CRWD

CrowdStrike Redefines Cybersecurity With Autonomous Charlotte AI Agentic Platform

SYNA

Synaptics Expands Veros Lineup With First Wi-Fi 7 SoCs Tailored For High-Performance, Low-Power IoT Applications

Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/ROP/earnings">opening bell on Monday, April 28.</a>
Analysts expect the Sarasota, Florida-based company to report quarterly earnings at $4.74 per share, up from $4.41 per share in the year-ago period. Roper Technologies projects to report quarterly revenue at $1.88 billion, compared to $1.68 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 24, Roper Technologies disclosed a deal to acquire CentralReach from Insight Partners for a net purchase price of around $1.65 billion.
Roper Technologies shares fell 0.4% to close at $557.70 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/rop/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Stephen Tusa maintained a Neutral rating and cut the price target from $558 to $465 on April 8, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Brad Reback initiated coverage on the stock with a Buy rating and a price target of $685 on March 27, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Oppenheimer analyst Christopher Glynn maintained an Outperform rating and raised the price target from $630 to $640 on Jan. 31, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Raymond James analyst Brian Gesuale reiterated a Strong Buy rating and increased the price target from $620 to $655 on Jan. 31, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Barclays analyst Julian Mitchell maintained an Underweight rating and cut the price target from $569 to $562 on Jan. 8, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying ROP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png" alt="" class="wp-image-890254" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Analyst Ratings

Roper Technologies Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<ul>
<li>TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients</li>
<li>TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients</li>
<li>Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events</li>
<li>On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025</li>
<li>Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET</li>
</ul>

TARA

Reported Saturday, Protara Therapeutics Shares Interim Results Highlighting Durable Clinical Responses With TARA-002 In High-Risk NMIBC

The authorities initially prioritized vaccination of adults aged 65 and over, especially those with comorbidities. On April 25, the French health authorities decided to suspend the use of IXCHIQ&#xAE; in persons aged 65 years and older pending further investigation. This is a response to an ongoing investigation of three cases of SAEs resulting in hospitalization, including one death, after vaccination with IXCHIQ&#xAE; among people in La Reunion. The three individuals who were hospitalized were over 80 years old and had pre-existing comorbidities3. These SAEs were reported through the pharmacovigilance system set up by the French health authorities, and causality has not been definitively established. The HAS maintains its current recommendation for IXCHIQ&#xAE; for people aged 18 to 64 years old as part of the ongoing vaccination campaign.

VALN

Reported Saturday, Valneva Provides Update On IXCHIQ Chikungunya Vaccine Use Following HAS Recommendation And Safety Investigation

<ul>
<li>Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone</li>
<li>Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years</li>
<li>Results have been shared with global health authorities to support potential regulatory filings</li>
</ul>

Reported Saturday, Pfizer's Sasanlimab Combination Therapy Shows Strong Event-Free Survival Gains In High-Risk Non-Muscle Invasive Bladder Cancer

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy
95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population

Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival

<ul>
<li>Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C</li>
<li>58.3% of patients showed durable complete responses by K-M at 24 months</li>
<li>97.3% of all treated patients remained free from progression to MIBC at 24 month</li>
<li>91.6% of responders remained cystectomy-free at 24 month</li>
<li>No Grade 3 or greater treatment-related adverse events or deaths reported</li>
<li>Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M</li>
<li>Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025</li>
</ul>

CGON

Reported Saturday, CG Oncology Reports Durability In BOND-003 Cohort C And Encouraging Early Results In Cohort P For Cretostimogene Grenadenorepvec

A man has become the first non-verbal, as well as only the third person ever, to receive a Neuralink Brain-Chip Interface (BCI) implant.
What Happened: Author Bradford G Smith suffers from ALS or Amyotrophic Lateral Sclerosis, a very rare nervous system disease that severely impacts motor functions. Smith released a video on the social media platform X to share the update on Sunday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am the 3rd person in the world to receive the <a href="https://twitter.com/neuralink?ref_src=twsrc%5Etfw">@Neuralink</a> brain implant. 1st with ALS. 1st Nonverbal. I am typing this with my brain. It is my primary communication. Ask me anything! I will answer at least all verified users! Thank you <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>! <a href="https://t.co/bxYO3SBfA2">pic.twitter.com/bxYO3SBfA2</a>
&mdash; Bradford G Smith (Brad) (@ALScyborg) <a href="https://twitter.com/ALScyborg/status/1916630186382291242?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Smith says that he uses the Neuralink implant to control the cursor on his laptop as well as Grok AI to create a clone of his own voice to speak. The video Smith shared was also edited by the BCI chip.
Why It Matters: The news comes as Elon Musk has touted his Neuralink BCI as technology that will help completely <a href="https://www.benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes">blind people see again</a>, the billionaire shared.&nbsp;&nbsp;
Musk also reiterated that robots would <a href="https://www.benzinga.com/25/04/45031447/elon-musk-says-the-best-human-surgeons-have-just-five-years-before-robots-overtake-them-reveals-instance-when-neuralink-had-to-use-a-robot-for-task-impossible-for-a-human">outperform human surgeons</a> in almost 5 years. He said Neuralink "had to use a robot for the brain-computer electrode insertion, as it was impossible for a human to achieve the required speed and precision."
Elsewhere, Neuralink is also eyeing an<a href="https://www.benzinga.com/general/biotech/25/04/44972585/elon-musks-neuralink-eyes-8-5-billion-pre-money-valuation-in-latest-funding-round-report"> $8.5 billion pre-money valuation</a> in its latest round of funding as the company aims to raise over $500 million, in ongoing talks with investors.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk&#8217;s Brain Chip</a></li>
</ul>
Image Via Shutterstock

Biotech

Man Battling ALS Becomes First Non-Verbal Patient To Receive Elon Musk's Neuralink Brain Implant

As AI chatbots like OpenAI's ChatGPT, Anthropic's Claude, and Perplexity reshape how users search for information, brands are adjusting their strategies to maintain visibility in this new search environment, which is increasingly displacing traditional search engines like Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: In a shift that threatens Google's dominance, brands are adopting new strategies to ensure they remain visible in the results generated by AI chatbots, <a href="https://www.ft.com/content/9cc6cc0b-759f-4b8e-9ed1-9e32ad0fe22f">reported</a> the Financial Times on Sunday.
Instead of clicking through to websites, many users now rely on AI's synthesized responses, which have decreased web traffic by up to 25%, the report noted, citing research from consultancy Bain.
Taking cognizance of this development, companies like Brandtech and Profound have developed tools that monitor how often brands appear in AI-driven responses, providing insights on how businesses can optimize for these models.
See Also: <a href="https://www.benzinga.com/25/04/44982688/alphabet-q1-earnings-preview-google-parent-stock-at-fork-in-the-road-while-antitrust-concerns-remain" target="_blank" rel="noreferrer noopener">Alphabet Q1 Earnings Preview: Google Parent Stock At ‘Fork In The Road,' While Antitrust Concerns Remain</a>
"This is about much more than just getting your website indexed in their results. This is about recognizing large language models as the ultimate influencer," said Jack Smyth, partner at Brandtech.
Brandtech has developed a &#8220;Share of Model&#8221; tool that helps brands analyze their visibility in AI search results and provides recommendations for optimizing website text and images.&nbsp;
Profound, which secured $3.5 million in seed funding in August, led by Khosla Ventures, offers a data analytics platform that enables brands to monitor popular industry queries and assess their standing within AI search results, the report said.
Why It's Important: On Thursday, Alphabet <a href="https://www.benzinga.com/25/04/44995955/alphabet-q1-earnings-highlights-google-search-youtube-cloud-show-robust-momentum">posted first-quarter revenue</a> of $90.23 billion, a 12% rise compared to the same period last year, beating Wall Street's expectation of $89.2 billion. Revenue from Google Search reached $50.7 billion, up from $46.2 billion a year earlier.
&nbsp;The strong performance helped ease investor concerns about rising competition from AI chatbots like Elon Musk's Grok and fears that Google's own Gemini chatbot and AI-generated summaries might be cutting into its traditional ad-driven search traffic, the report said.
Deepwater Asset Management's Gene Munster previously said that Google's existing search format, which blends AI overviews, blue links, and organic results, <a href="https://www.benzinga.com/25/04/44999838/can-google-adapt-like-amazon-or-will-it-face-ebays-fate-gene-munsters-candid-take-on-the-search-giants-path-forward-in-the-age-of-ai">may fall short against newer</a>, more streamlined search experiences offered by models like Grok, ChatGPT, and Claude.
Price Action: In after-hours trading, Alphabet Inc.&#8217;s Class A shares slipped 0.16% to $161.70, while Class C shares dipped 0.1% to $163.68, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Alphabet holds a growth score of 64.44%, based on Benzinga Edge Stock Rankings. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it compares to other companies</a> in the sector.
Photo Courtesy: Ascannio On Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44986406/if-you-invested-1000-in-google-stock-when-it-acquired-youtube-heres-how-much-youd-have-today" target="_blank" rel="noreferrer noopener">If You Invested $1,000 in Google Stock When It Acquired YouTube, Here's How Much You'd Have Today</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

GOOG

GOOGL

Google Faces Growing Threat As Chatbots Reshape How Users Search For Brands: Are ChatGPT, Claude And Others AI Bots Set To Be The 'Ultimate' Influencers?

Chinese manufacturers are suspending operations and pursuing alternative markets as U.S. tariff increases take effect, creating ripple effects across global supply chains and threatening millions of jobs.
What Happened: Chinese factories are pausing production due to the impact of U.S. tariffs, as <a href="https://www.cnbc.com/2025/04/28/chinese-factories-stop-production-eye-new-markets-as-us-tariffs-hit.html?ref=biztoc.com">reported</a> by CNBC on Monday. The lost orders are affecting jobs and prompting Chinese exporters to explore new sales strategies, such as livestreaming at home.
According to Cameron Johnson, a senior partner at consulting firm Tidalwave Solutions, factories producing toys, sporting goods, and low-cost Dollar Store-type goods are currently the most affected. &#8220;While not large-scale yet, it is happening in the key [export] hubs of Yiwu and Dongguan, and there is concern that it will grow,&#8221; Johnson said. The impact of recent tariff hikes exceeding 100% is &#8220;way bigger&#8221; than the COVID-19 pandemic&#8217;s disruption, says Ash Monga, CEO of Imex Sourcing Services. 
Woodswool, an athleticwear manufacturer near Shanghai, reports all U.S. orders have been canceled, with over half its production once destined for American customers. The company has pivoted to domestic sales through Baidu&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) livestreaming platform, though its new sales channel generates only modest revenue.
See Also: <a href="https://www.benzinga.com/25/04/44999959/how-the-us-china-trade-war-is-unintentionally-boosting-demand-for-intels-older-chips-amid-economic-uncertainty">Intel&#8217;s Older Parts Are In Demand Thanks To US-China Trade War: &#8216;Tariffs Have Everybody Hedging Their Bets,&#8217; Says Executive</a>
Why It Matters: Many companies are diversifying production to India over Southeast Asia, while others are turning from U.S. customers to those in Europe and Latin America. Some companies have already built businesses on other trade routes from China.
For U.S. investors, these developments signal potential disruption in supply chains and pricing. Goldman Sachs has downgraded China&#8217;s Gross Domestic Product growth <a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns?utm_source=chatgpt.com">forecasts to 4.0% for 2025 and 3.5% for 2026</a>, below the government&#8217;s 5% target.
The U.S.-China trade war, under President Donald Trump&#8216;s administration, has led to a <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">significant decrease in U.S. imports </a>from China. In response, China has started to<a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts"> exempt some U.S. imports</a> from high tariffs, indicating a possible easing of trade tensions.
The iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>), a widely followed U.S.-listed fund that tracks major Chinese companies, has fallen 4.38% since Trump introduced a 34% &#8220;reciprocal&#8221; tariff on Chinese imports.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45005825/us-has-tons-of-solutions-to-secure-rare-earth-production-if-china-halts-exports-experts-say-but-warn-of-significant-challenges">US Has &#8216;Tons Of Solutions&#8217; To Secure Rare Earth Production If China Halts Exports, Experts Say, But Warn Of Significant Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

BIDU

Trump Tariffs Prompt Suspension Of Chinese Factory Operations And Shift To New Markets

<ul>
<li>Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as&nbsp;a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to&nbsp;the U.S. Food and Drug Administration</li>
</ul>

Reported Saturday, Medtronic's Hugo RAS System Achieves 98.5% Surgical Success Rate In Largest U.S. Robotic-Assisted Urology Study

Legal

Press Releases

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Health Care

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Financing

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ)

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

CROX

DRVN

EXTR

IART

KYTX

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Alkermes

Alvotech

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

ImmunityBio

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

B of A Securities

Morgan Stanley

Citigroup

이 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아케로 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/43231670" target="_blank" rel="noreferrer noopener">에프룩시퍼민(Efruxifermin)에 대한 SYMMETRY 2B상 연구</a>의 96주차 예비 결과를 보고한 후 주가는 106.57% 급등했다. 몇몇 애널리스트들이 <a href="https://www.benzinga.com/quote/akro/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 상향 조정</a>했다.
2. 서저리 파트너스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43281237" target="_blank" rel="noreferrer noopener">베인 캐피탈 프라이빗 에쿼티로부터 비구속적 인수 제안을 받았다고 발표한 후 25.44% 상승</a>했다.
3. 플래그스타 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>)의 주가가 24.40% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/43330170" target="_blank" rel="noreferrer noopener">예상보다 좋은 재무 결과를 발표</a>한 후 바클레이즈의 애널리스트 자레드 쇼(Jared Shaw)가 비중 확대를 유지하고 <a href="https://www.benzinga.com/quote/flg/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격을 13달러에서 14달러로 상향 조정</a>했기 때문이다.
4. 넥스트랙커(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>)의 주가가 22.98% 상승했다. 이는 회사가 2025 회계연도 3분기 재무 실적이 예상보다 좋게 나타났고 가이던스를 상향 조정했다고 발표한 후 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43319444" target="_blank" rel="noreferrer noopener">목표 주가를 수정</a>했기 때문이다.
5. 브라이트하우스 파이낸셜(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>)의 주가가 21.76% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/43275032" target="_blank" rel="noreferrer noopener">잠재적 매각을 검토 중이라는 보고서</a> 이후 바클레이즈의 애널리스트 알렉스 스캇(Alex Scott)이 회사를 중립에서 비중 확대으로 상향 조정하고 <a href="https://www.benzinga.com/quote/bhf/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격을 52달러에서 85달러로 상향 조정</a>했기 때문이다.
6. 브링커 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>)의 주식이 21.72% 상승했다. 이는 회사가 2분기 실적이 예상보다 좋게 나타났고 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43335877" target="_blank" rel="noreferrer noopener">가격 예측을 변경</a>했다고 발표한 후 발생한 일이다.
7. 힘스 &amp; 허스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)의 주식이 20.76% 상승했다.
8. 오시코시 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>)의 주식이 19.38% 급등했다. 이는 회사가 4분기 실적을 예상보다 높게 발표하고 FY25 EPS 가이던스를 예상보다 높게 설정하며 <a href="https://www.benzinga.com//node/43331819" target="_blank" rel="noreferrer noopener">분기 배당금을 11% 인상</a>한 후 애널리스트들이 <a href="https://www.benzinga.com/quote/osk/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 상향 조정</a>했기 때문이다.
9. 킹소프트 클라우드 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>)의 주식이 16.50% 상승했다. 이는 설날, 최근 중국의 AI 발전 및 정부의 시장 부양 노력으로 인한 것으로 보인다.
10. 비아비 솔루션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>)의 주식이 14.78% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/43353084" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 재무 결과를 발표</a>한 후 발생한 일이다.
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%8C%EB%A6%AC%EB%B0%94%EB%B0%94-ibm-%EB%B0%8F-%EB%93%80%EC%98%A4%EB%A7%81%EA%B3%A0-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">알리바바, IBM 및 듀오링고 지난주 최고 성과를 보여준 10개 대형주 중 일부 (1월 27일-1월 31일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%ED%85%8C%EB%B0%94-%ED%8C%8C%EB%A7%88-%EB%B0%8F-ups-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-12%EA%B0%9C%EC%9D%98-%EB%8C%80%ED%98%95/" target="_blank" rel="noopener">엔비디아, 테바 파마 및 UPS 등 지난주 하락한 12개의 대형주 (1월 27일-1월 31일)</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Akero Therapeutics

뉴스

에 대한 최신 뉴스 Akero Therapeutics (NASDAQ:AKRO) 주식

일요일, 2월 02, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌